Xue Li

Xue Li

Auto-generated profile, based on publicly available information

Xue Li

Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2023 in eClinicalMedicine
Verified
Journal Article
Open access
KPKuan Peng
Kuan Peng
XLXue Li
Xue Li
DYDeliang Yang
Deliang Yang
SCShirley C.W. Chan
Shirley C.W. Chan
JZJiayi Zhou
Jiayi Zhou
IWIan Chi Kei Wong
Ian Chi Kei Wong
Case reports suggest that SARS-CoV-2 infection could lead to immune dysregulation and trigger autoimmunity while COVID-19 vaccination is effective against severe COVID-19 outcomes. We aim to examine the association between COVID-19 and development of autoimmune diseases (ADs), and the potential protective effect of COVID-19 vaccination on such an association. A retrospective cohort study was conducted in Hong Kong between 1 April 2020 and 15 November 2022. COVID-19 was confirmed by positive polymerase chain reaction or rapid antigen test. Cox proportional hazard regression with inverse probability of treatment weighting was applied to estimate the risk of incident ADs following COVID-19. COVID-19 vaccinated population was compared against COVID-19 unvaccinated population to examine the protective effect of COVID-19 vaccination on new ADs. The study included 1,028,721 COVID-19 and 3,168,467 non-COVID individuals. Compared with non-COVID controls, patients with COVID-19 presented an increased risk of developing pernicious anaemia [adjusted Hazard Ratio (aHR): 1.72; 95% Confidence Interval (CI): 1.12–2.64]; spondyloarthritis [aHR: 1.32 (95% CI: 1.03–1.69)]; rheumatoid arthritis [aHR: 1.29 (95% CI: 1.09–1.54)]; other autoimmune arthritis [aHR: 1.43 (95% CI: 1.33–1.54)]; psoriasis [aHR: 1.42 (95% CI: 1.13–1.78)]; pemphigoid [aHR: 2.39 (95% CI: 1.83–3.11)]; Graves' disease [aHR: 1.30 (95% CI: 1.10–1.54)]; anti-phospholipid antibody syndrome [aHR: 2.12 (95% CI: 1.47–3.05)]; immune mediated thrombocytopenia [aHR: 2.1 (95% CI: 1.82–2.43)]; multiple sclerosis [aHR: 2.66 (95% CI: 1.17–6.05)]; vasculitis [aHR: 1.46 (95% CI: 1.04–2.04)]. Among COVID-19 patients, completion of two doses of COVID-19 vaccine shows a decreased risk of pemphigoid, Graves' disease, anti-phospholipid antibody syndrome, immune-mediated thrombocytopenia, systemic lupus erythematosus and other autoimmune arthritis. Our findings suggested that COVID-19 is associated with an increased risk of developing various ADs and the risk could be attenuated by COVID-19 vaccination. Future studies investigating pathology and mechanisms would be valuable to interpreting our findings. Supported by RGC Collaborative Research Fund (C7154-20GF).

25 January 2022 in Annals of Internal Medicine
Verified
Journal Article
Open access
FLFrancisco Lai
Francisco Lai
XLXue Li
Xue Li
KPKuan Peng
Kuan Peng
LHLei Huang
Lei Huang
PIPatrick Ip
Patrick Ip
IWIan Chi Kei Wong
Ian Chi Kei Wong
This case–control study from Hong Kong examined the association between COVID-19 vaccination with an mRNA vaccine or an inactivated virus vaccine and subsequent risk for carditis. The results could... Visual Carditis Risk After Messenger RNA and Inactivated Virus Vaccination. This case–control study from Hong Kong examined the association between COVID-19 vaccination with an mRNA vaccin... Background: Case reports of carditis after BNT162b2 vaccination are accruing worldwide. Objective: To examine the association of BNT162b2 and CoronaVac (Sinovac) vaccination with carditis. Design: ...

1 December 2020 in Value in Health
Verified
Journal Article
Open access
ACAdrienne Y.L. Chan
Adrienne Y.L. Chan
VCVivien K.Y. Chan
Vivien K.Y. Chan
SOSten Olsson
Sten Olsson
MFMin Fan
Min Fan
MJMark Jit
Mark Jit
XLXue Li
Xue Li
Three hundred million people living with rare diseases worldwide are disproportionately deprived of in-time diagnosis and treatment compared with other patients. This review provides an overview of global policies that optimize development, licensing, pricing, and reimbursement of orphan drugs. Pharmaceutical legislation and policies related to access and regulation of orphan drugs were examined from 194 World Health Organization member countries and 6 areas. Orphan drug policies (ODPs) were identified through internet search, emails to national pharmacovigilance centers, and systematic academic literature search. Texts from selected publications were extracted for content analysis. One hundred seventy-two drug regulation documents and 77 academic publications from 162 countries/areas were included. Ninety-two of 200 countries/areas (46.0%) had documentation on ODPs. Thirty-four subthemes from content analysis were categorized into 6 policy themes, namely, orphan drug designation, marketing authorization, safety and efficacy requirements, price regulation, incentives that encourage market availability, and incentives that encourage research and development. Countries/areas with ODPs were statistically wealthier (gross national income per capita = $10 875 vs $3950, P < .001). Country/area income was also positively correlated with the scope of the respective ODP (correlation coefficient = 0.57, P < .001). Globally, the number of countries with an ODP has grown rapidly since 2013. Nevertheless, disparities in geographical distribution and income levels affect the establishment of ODPs. Furthermore, identified policy gaps in price regulation, incentives that encourage market availability, and incentives that encourage research and development should be addressed to improve access to available and affordable orphan drugs.

26 February 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
ILIvan Chun Hang Lam
Ivan Chun Hang Lam
RZRan Zhang
Ran Zhang
KMKenneth Keng Cheung Man
Kenneth Keng Cheung Man
CWCarlos K H Wong
Carlos K H Wong
CCCeline Sze Ling Chui
Celine Sze Ling Chui
EWEric Yuk Fai Wan
Eric Yuk Fai Wan
The persisting risk of long-term health consequences of SARS-CoV-2 infection and the protection against such risk conferred by COVID-19 vaccination remains unclear. Here we conducted a retrospective territory-wide cohort study on 1,175,277 patients with SARS-CoV-2 infection stratified by their vaccination status and non-infected controls to evaluate the risk of clinical sequelae, cardiovascular and all-cause mortality using a territory-wide public healthcare database with population-based vaccination records in Hong Kong. A progressive reduction in risk of all-cause mortality was observed over one year between patients with SARS-CoV-2 infection and controls. Patients with complete vaccination or have received booster dose incurred a lower risk of health consequences including major cardiovascular diseases, and all-cause mortality than unvaccinated or patients with incomplete vaccination 30-90 days after infection. Completely vaccinated and patients with booster dose of vaccines did not incur significant higher risk of health consequences from 271 and 91 days of infection onwards, respectively, whilst un-vaccinated and incompletely vaccinated patients continued to incur a greater risk of clinical sequelae for up to a year following SARS-CoV-2 infection. This study provided real-world evidence supporting the effectiveness of COVID-19 vaccines in reducing the risk of long-term health consequences of SARS-CoV-2 infection and its persistence following infection.

13 June 2023 in Journal of Internal Medicine
Verified
Journal Article
Open access
XTXinning Tong
Xinning Tong
CSChin‐Yao Shen
Chin‐Yao Shen
HJHa-Lim Jeon
Ha-Lim Jeon
YLYihua Li
Yihua Li
JSJu-Young Shin
Ju-Young Shin
Edward Chia-Cheng LaiEdward Chia-Cheng Lai
Edward Chia-Cheng Lai
Background: This study aimed to compare the cardiovascular safety of interleukin‐6 inhibitors (IL‐6i) and Janus Kinase inhibitors (JAKi) to tumour necrosis factor inhibitors (TNFi).Methods: We conducted a retrospective cohort study using population‐based electronic databases from Hong Kong, Taiwan and Korea. We identified newly diagnosed patients with rheumatoid arthritis (RA) who received b/tsDMARDs first time. We followed patients from b/tsDMARD initiation to the earliest outcome (acute coronary heart disease, stroke, heart failure, venous thromboembolism and systemic embolism) or censoring events (death, transformation of b/tsDMARDs on different targets, discontinuation and study end). Using TNFi as reference, we applied generalized linear regression for the incidence rate ratio estimation adjusted by age, sex, disease duration and comorbidities. Random effects meta‐analysis was used for pooled analysis.Results: We identified 8689 participants for this study. Median (interquartile range) follow‐up years were 1.45 (2.77) in Hong Kong, 1.72 (2.39) in Taiwan and 1.45 (2.46) in Korea. Compared to TNFi, the adjusted incidence rate ratios (aIRRs) (95% confidence interval [CI]) of IL‐6i in Hong Kong, Taiwan and Korea are 0.99 (0.25, 3.95), 1.06 (0.57, 1.98) and 1.05 (0.59, 1.86) and corresponding aIRR of JAKi are 1.50 (0.42, 5.41), 0.60 (0.26, 1.41), and 0.81 (0.38, 1.74), respectively. Pooled aIRRs showed no significant risk of cardiovascular events (CVEs) associated with IL‐6i (1.05 [0.70, 1.57]) nor JAKi (0.80 [0.48, 1.35]) compared to TNFi.Conclusion: There was no difference in the risk of CVE among RA patients initiated with IL‐6i, or JAKi compared to TNFi. The finding is consistent in Hong Kong, Taiwan and Korea.

20 January 2010 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HGHui-Fang Guo
Hui-Fang Guo
HSHua-Yi Shao
Hua-Yi Shao
ZYZhao-Yong Yang
Zhao-Yong Yang
SXSi-Tu Xue
Si-Tu Xue
XLXue Li
Xue Li
ZLZhuo-Rong Li
Zhuo-Rong Li